Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Cash from Financing Activities (2018 - 2025)

Inmune Bio (INMB) has disclosed Cash from Financing Activities for 8 consecutive years, with $67000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 103.22% to $67000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.6 million through Dec 2025, up 51.62% year-over-year, with the annual reading at $27.6 million for FY2025, 51.62% up from the prior year.
  • Cash from Financing Activities hit $67000.0 in Q4 2025 for Inmune Bio, down from $22.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $52.9 million in Q3 2021 to a low of -$2.5 million in Q4 2023.
  • Historically, Cash from Financing Activities has averaged $11.7 million across 5 years, with a median of $7.5 million in 2024.
  • Biggest five-year swings in Cash from Financing Activities: soared 316366.67% in 2021 and later plummeted 97.44% in 2022.
  • Year by year, Cash from Financing Activities stood at $52.9 million in 2021, then plummeted by 98.62% to $729000.0 in 2022, then crashed by 442.94% to -$2.5 million in 2023, then grew by 16.88% to -$2.1 million in 2024, then soared by 103.22% to $67000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for INMB at $67000.0 in Q4 2025, $22.3 million in Q2 2025, and $5.3 million in Q1 2025.